Edwards Lifesciences Corporation $EW Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC lessened its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 96.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 316,392 shares of the medical research company’s stock after selling 9,784,074 shares during the period. Fisher Asset Management LLC owned about 0.05% of Edwards Lifesciences worth $24,745,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Norges Bank purchased a new stake in shares of Edwards Lifesciences during the second quarter valued at $580,640,000. Nuveen LLC acquired a new stake in Edwards Lifesciences during the 1st quarter worth about $330,881,000. Jennison Associates LLC raised its holdings in Edwards Lifesciences by 15.7% during the 2nd quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock worth $912,788,000 after buying an additional 1,584,958 shares during the period. Primecap Management Co. CA lifted its stake in Edwards Lifesciences by 49.9% during the second quarter. Primecap Management Co. CA now owns 3,446,891 shares of the medical research company’s stock valued at $269,581,000 after buying an additional 1,147,291 shares in the last quarter. Finally, Mirova US LLC boosted its holdings in shares of Edwards Lifesciences by 56.2% in the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock worth $229,257,000 after buying an additional 1,054,301 shares during the period. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Price Performance

EW opened at $84.67 on Wednesday. The stock has a fifty day moving average price of $80.36 and a 200 day moving average price of $78.59. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.40. The stock has a market cap of $49.14 billion, a price-to-earnings ratio of 36.50, a PEG ratio of 3.78 and a beta of 0.97.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business’s quarterly revenue was up 14.7% on a year-over-year basis. During the same period last year, the business earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of the firm’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total transaction of $84,201.00. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,314,725.84. This represents a 24.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on EW. Raymond James Financial upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target on the stock in a report on Monday, November 3rd. Robert W. Baird set a $83.00 price objective on shares of Edwards Lifesciences in a research report on Friday, October 31st. Barclays restated an “overweight” rating and issued a $99.00 target price (up previously from $95.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. Canaccord Genuity Group reiterated a “hold” rating and set a $84.00 price target (up previously from $81.00) on shares of Edwards Lifesciences in a report on Monday, November 3rd. Finally, Stifel Nicolaus upped their price target on Edwards Lifesciences from $85.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $91.39.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.